The NKD2 Knockout Raji Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal population of Raji B lymphocytes with targeted disruption of the NKD2 gene. This loss-of-function cell pool enables systematic study of NKD2-dependent processes without clone-specific artifacts. The polyclonal format ensures consistent gene ablation across the population, suitable for bulk biochemical and functional analyses.
Raji is an EBV-positive Burkitt’s lymphoma cell line that models aggressive B-cell malignancy. Its viral transformation and MYC dysregulation provide a relevant background for probing regulators of oncogenic signaling in hematologic cancers. This cellular context is instrumental for dissecting how endogenous pathway modulators influence lymphoma cell behavior.
NKD2 acts as a negative regulator of canonical Wnt/??-catenin signaling by binding to DVL1, DVL2, and DVL3, anchoring them at the plasma membrane. This prevents DVL-mediated suppression of the ??-catenin destruction complex, allowing GSK3?? and CKI to phosphorylate ??-catenin for proteasomal degradation. Consequently, NKD2 reduces TCF/LEF-driven transcription of targets such as MYC, CCND1, and AXIN2. Upstream, WNT3A and WNT5A through Frizzled receptors and LRP5/6 coreceptors modulate this interaction. The pathway also includes APC, AXIN, and ??-catenin (CTNNB1), placing NKD2 at a critical node controlling ??-catenin nuclear shuttling and target gene expression.
In Raji B-lymphoma cells, Wnt pathway dysregulation contributes to malignant phenotypes. EBV latent gene products can intersect with Wnt signaling, and ??-catenin hyperactivity is observed in some B-cell lymphomas. Abolishing NKD2 lifts a key constraint on Wnt transduction, potentially enhancing proliferative and survival signals. These NKD2 knockout polyclonal cells thus enable investigation of how loss of this negative regulator reshapes oncogenic networks specific to B-cell contexts, free from clonal variance.
Applications include western blotting for ??-catenin and DVL, RT-qPCR of MYC and CCND1, and TOPFlash/FOPFlash luciferase assays to assess Wnt pathway output. Flow cytometry facilitates cell cycle profiling, while co-immunoprecipitation verifies disrupted NKD2-DVL complexes. This model supports drug screening for Wnt inhibitors and functional genomics studies in lymphoma. For additional information on protocols, contact Ascent Research.
